利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

3 条记录 (耗时 0.037 秒)

    HLA-restricted hepatitis B virus CTL epitopes
    1.
    发明公开
    HLA-restricted hepatitis B virus CTL epitopes 失效
    HLA-reduzierte CTL-Epitope gegen Hepatite B-Virus

    公开(公告)号：EP1018344A2

    公开(公告)日：2000-07-12

    申请号：EP00102538.6

    申请日：1992-08-26

    申请人： Epimmune, Inc.

    发明人： Vitiello, Maria A. ,  Chesnut, Robert W.

    IPC分类号： A61K39/29 ,  A61K47/48 ,  C07K14/02 ,  C07K19/00 ,  C07K14/33 ,  A61K39/08 ,  G01N33/68

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/57 ,  C07K2319/00 ,  C12N2730/10122

    摘要： Cytotoxic T lymphocyte-stimulating peptides induce HLA-restricted responses to hepatitis B virus antigens. The peptides, derived from CTL epitopic regions of both HBV surface and nucleocapsid antigens, are particularly useful in the treatment and prevention of HBV infection, including the treatment of chronically infected HBV carriers. The peptides can be formulated as HBV vaccines and pharmaceutical compositions, such as lipid-containing compositions for enhancing the HLA-restricted CTL responses. The peptides are also useful in diagnostic methods, such as predicting which HBV-infected individuals are prone to developing chronic infection.

    摘要翻译： 细胞毒性T淋巴细胞刺激肽诱导HLA受限于乙型肝炎病毒抗原的应答。 衍生自HBV表面和核衣壳抗原的CTL表位区的肽特别可用于治疗和预防HBV感染，包括治疗慢性感染的HBV携带者。 肽可以配制成HBV疫苗和药物组合物，例如用于增强HLA限制性CTL应答的含脂质组合物。 这些肽也可用于诊断方法，例如预测哪些HBV感染个体易发展为慢性感染。

    HLA-restricted hepatitis B virus CTL epitopes
    2.
    发明公开
    HLA-restricted hepatitis B virus CTL epitopes 失效
    HLA-减少对Hepatite乙型肝炎病毒CTL表位

    公开(公告)号：EP1018344A3

    公开(公告)日：2000-09-20

    申请号：EP00102538.6

    申请日：1992-08-26

    申请人： Epimmune, Inc.

    发明人： Vitiello, Maria A. ,  Chesnut, Robert W.

    IPC分类号： C12N15/51 ,  A61K39/29 ,  G01N33/569 ,  C07K7/00

    CPC分类号： C07K14/005 ,  A61K39/00 ,  A61K2039/57 ,  C07K2319/00 ,  C12N2730/10122

    摘要： Cytotoxic T lymphocyte-stimulating peptides induce HLA-restricted responses to hepatitis B virus antigens. The peptides, derived from CTL epitopic regions of both HBV surface and nucleocapsid antigens, are particularly useful in the treatment and prevention of HBV infection, including the treatment of chronically infected HBV carriers. The peptides can be formulated as HBV vaccines and pharmaceutical compositions, such as lipid-containing compositions for enhancing the HLA-restricted CTL responses. The peptides are also useful in diagnostic methods, such as predicting which HBV-infected individuals are prone to developing chronic infection.